Cargando…
Women with Pregnancies Had Lower Adherence to 1% Tenofovir Vaginal Gel as HIV Preexposure Prophylaxis in CAPRISA 004, a Phase IIB Randomized-Controlled Trial
BACKGROUND: Antiretroviral prophylaxis may be a critical strategy to reduce periconception HIV transmission. Maximizing the benefit of periconception pharmacologic HIV risk-reduction requires an understanding of the links between pregnancy and adherence to this prevention strategy. METHODS: We asses...
Autores principales: | Matthews, Lynn T., Sibeko, Sengeziwe, Mansoor, Leila E., Yende-Zuma, Nonhlanhla, Bangsberg, David R., Karim, Quarraisha Abdool |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3589407/ https://www.ncbi.nlm.nih.gov/pubmed/23472071 http://dx.doi.org/10.1371/journal.pone.0056400 |
Ejemplares similares
-
Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial
por: Karim, Quarraisha Abdool, et al.
Publicado: (2011) -
Age-Restriction of a Validated Risk Scoring Tool Better Predicts HIV Acquisition in South African Women: CAPRISA 004
por: Castor, Delivette, et al.
Publicado: (2022) -
Trial participation disclosure and gel use behavior in the CAPRISA 004 tenofovir gel trial
por: Succop, Stacey M., et al.
Publicado: (2014) -
Infrequent, low magnitude HIV-specific T cell responses in HIV-uninfected participants in the 1% tenofovir microbicide gel trial (CAPRISA004)
por: Burgers, WA, et al.
Publicado: (2012) -
Assessing Adherence in the CAPRISA 004 Tenofovir Gel HIV Prevention Trial: Results of a Nested Case–Control Study
por: MacQueen, Kathleen M., et al.
Publicado: (2014)